Biomarkers for neurological disorders are urgently needed3
Neurological disorders, such as Alzheimer’s disease and other dementias, brain injury, Parkinson’s disease and others, would ideally exhibit a unique pathology to allow clinicians to distinguish particular conditions and give a reliable diagnosis and treatment.3
In reality, however, many neurodegenerative diseases share similar symptoms and features and the task of diagnosis is often challenging.3
Biomarkers are urgently needed to aid diagnosis, monitor disease progression and as new medicines are introduced, detect the patient’s response to treatment.3
References
- Tarun Dua et al. Neurological disorders. Public health challenges, Geneva, World Health Organization Press, 2006.
- Valery L Feigin et al. The Lancet Neurology, 2017, 16 (11): 877-897
- Ward M. et al. Therapy, 2010, 7(4): 321–336
- Alzheimer’s Disease International. World Alzheimer Report 2018. Available at:https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf
- https://www.alzheimer-europe.org/Research/Value-of-Knowing
- https://www.who.int/news-room/fact-sheets/detail/dementia
- Jack CR Jr, et al. Lancet Neurol 2010;9:119–28